XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Capital in Excess of Par Value
Accumulated Income
Treasury Stock
Noncontrolling Interests
Balance at beginning of period (shares) at Dec. 31, 2022   99.8        
Balance at beginning of period at Dec. 31, 2022 $ 1,826.3 $ 1.1 $ 1,730.2 $ 115.7 $ (536.7) $ 516.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 337.7     264.4   73.3
Receipt of treasury stock (shares)   (0.1)        
Receipt of treasury stock (8.1)       (8.1)  
Dividends declared (45.4)   0.4 (45.8)    
Stock-based compensation 37.2   37.2      
Distributions declared (87.5)         (87.5)
Capital contributions from consolidated affiliates 87.0         87.0
Other (shares)   0.5        
Other 0.5 $ 0.1 3.8   (1.9) (1.5)
Balance at end of period (shares) at Sep. 30, 2023   100.2        
Balance at end of period at Sep. 30, 2023 2,147.7 $ 1.2 1,771.6 334.3 (546.7) 587.3
Balance at beginning of period (shares) at Jun. 30, 2023   100.2        
Balance at beginning of period at Jun. 30, 2023 2,017.7 $ 1.2 1,755.0 264.6 (545.5) 542.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 111.5     85.3   26.2
Receipt of treasury stock (0.4)       (0.4)  
Dividends declared (15.2)   0.4 (15.6)    
Stock-based compensation 13.7   13.7      
Distributions declared (28.8)         (28.8)
Capital contributions from consolidated affiliates 49.0         49.0
Other 0.2   2.5   (0.8) (1.5)
Balance at end of period (shares) at Sep. 30, 2023   100.2        
Balance at end of period at Sep. 30, 2023 2,147.7 $ 1.2 1,771.6 334.3 (546.7) 587.3
Balance at beginning of period (shares) at Dec. 31, 2023   100.3        
Balance at beginning of period at Dec. 31, 2023 2,255.2 $ 1.2 1,787.0 406.5 (547.2) 607.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 428.2     334.8   93.4
Receipt of treasury stock (shares)   (0.2)        
Receipt of treasury stock (12.1)       (12.1)  
Dividends declared (47.8)   0.3 (48.1)    
Stock-based compensation 35.8   35.8      
Distributions declared (94.5)         (94.5)
Capital contributions from consolidated affiliates 133.5         133.5
Repurchases of common stock in open market (shares)   (0.3)        
Repurchases of common stock in open market (23.6)       (23.6)  
Contribution of our hospital to consolidated joint venture (7.9)   22.9     (30.8)
Other (shares)   1.0        
Other 2.3   (7.8)   10.1  
Balance at end of period (shares) at Sep. 30, 2024   100.8        
Balance at end of period at Sep. 30, 2024 2,669.1 $ 1.2 1,838.2 693.2 (572.8) 709.3
Balance at beginning of period (shares) at Jun. 30, 2024   100.7        
Balance at beginning of period at Jun. 30, 2024 2,481.4 $ 1.2 1,806.8 602.3 (570.9) 642.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 145.9     108.2   37.7
Dividends declared (17.2)   0.1 (17.3)    
Stock-based compensation 12.9   12.9      
Distributions declared (36.4)         (36.4)
Capital contributions from consolidated affiliates 96.9         96.9
Repurchases of common stock in open market (shares)   (0.1)        
Repurchases of common stock in open market (6.8)       (6.8)  
Contribution of our hospital to consolidated joint venture (7.9)   22.9     (30.8)
Other (shares)   0.2        
Other 0.3   (4.5)   4.9 (0.1)
Balance at end of period (shares) at Sep. 30, 2024   100.8        
Balance at end of period at Sep. 30, 2024 $ 2,669.1 $ 1.2 $ 1,838.2 $ 693.2 $ (572.8) $ 709.3